Systolic heart failure in the elderly;Die systolische herzinsuffizienz des älteren

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 12, 2005, Pages 698-703

  Kilter, Heiko ^a   Bohm M ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; METOPROLOL; NEBIVOLOL; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; DIGITALIS GLYCOSIDE;

AGED; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG INDICATION; ELDERLY CARE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HUMAN; META ANALYSIS; PROGNOSIS; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; TREATMENT OUTCOME; CONGESTIVE HEART FAILURE; DIASTOLE; DRUG EFFECT; HEMODYNAMICS; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SURVIVAL RATE; SYSTOLE;

AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; DIASTOLE; DIGITALIS GLYCOSIDES; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; SURVIVAL RATE; SYSTOLE;

EID: 17144364375     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865082     Document Type: Review

References (39)

1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828
2. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533
3. Böhm M, Dorner H, Htun P, Lensche H, Platt D, Erdmann E. Effects of exercise on myocardial adenylate cyclase and Gi alpha expression in senescence. Am J Physiol 1993; 264: H805-814
4. Casale PN, Devereux RB, Milner M et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-178
5. Castellano M, Böhm M. The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 1997; 29: 715-722
6. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675
7. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JC. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004; 25: 1300-1309
8. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 3: 469-479
9. Esler MD, Thompson JM, Kaye DM et al. Effects of aging on the responsiveness of the human cardiac sympathetic nerves to stressors. Circulation 1995; 91: 351-358
10. Flather MD, Shibata MC, Coats AJ et al. Randomised Trial to Determine the Effect of Nebivolol on Mortality and Cardiovascular Hospital Admission in Elderly Patients with Heart Failure (SENIORS). Eur Heart J 2005; 26: 215-225
11. Flather MD, Yusuf S, Kober L et al. ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575-1581
12. Fleg JL, O'Connor F, Gerstenblith G et al. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. J Appl Physiol 1995; 78: 890-900
13. Gambassi G, Forman DE, Lapane KL et al. The SAGE Study Group. Management of heart failure among very old persons living in long-term care: has the voice of trials spread? Am Heart J 2000; 139: 85-93
14. Garg R, Yusuf S Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Jama 1995; 273: 1450-1456
15. Hunt SA, Baker DW, Chin MH et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001; 104: 2996-3007
16. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551
17. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951-957
18. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26:1257-1263
19. Kitzman DW, Gardin JM, Gottdiener JS et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001; 87: 413-419
20. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352
21. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation 2003; 107: 139-146
22. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 2003; 107: 346-354
23. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 59: 956-960
24. Masoudi FA, Havranek EP, Wolfe P et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003; 146: 250-257
25. McCullough PA, Hollander JE, Nowak RM et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003; 10: 198-204
26. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658
27. Packer M, Conn JN, Abrahem WT et al. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83: 1A-38A
28. Packer M, Poole-Wilson PA, Armstrong PW et al. ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-2318
29. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766
30. Philbin EF, Jr. Rocco TA, Lindenmuth NW, Ulrich K, Jenkins PL. Clinical outcomes in heart failure: report from a community hospital-based registry. Am J Med 1999; 107: 549-555
31. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587
32. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321
33. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752
34. Pitt B, Zannad F, Remme WJ et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717
35. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-878
36. Rich MW. Management of heart failure in the elderly. Heart Fail Rev 2002; 7: 89-97
37. Rodeheffer RJ, Gerstenblith G, Becker LC, Fleg JL, Weisfeldt ML, Lakatta EG. Exercise cardiac output is maintained with advancing age in healthy human subjects: cardiac dilatation and increased stroke volume compensate for a diminished heart rate. Circulation 1984; 69: 203-213
38. Xiao RP, Tomhave ED, Wang DJ et al. Age-associated reductions in cardiac beta1- and beta2-adrenergic responses without changes in inhibitory G proteins or receptor kinases. J Clin Invest 1998; 101: 1273-1282
39. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153